About Us

GEUS Technology

Aniling owns the GEUS technology, which unifies genetic and epigenetic sequencing and provides end-to-end solutions for the right treatment decisions in oncology. Based on GEUS, Aniling is developing a set of products for cancer diagnostic.


The first Aniling product is the most comprehensive Chronic Lymphocytic Leukemia Next Generation Sequencing diagnostics panel. The GEUS-CLL delivers accurate staging and treatment decisions. Aniling S.L. provides the GEUS-CLL diagnostic test as a service to other laboratories and hospitals.

Latest News

Aniling Renews ISO 13485:2016 Certification

Aniling, a biotechnology company specialized in diagnostics using a unique and proprietary technology analyzing both genomic and epigenomic biomarkers, is proud to announce the successful renewal of its ISO 13485:2016 certification, …

Colorectal Cancer Day 2024

📣 Colorectal cancer is the third most common cancer worldwide, accounting for approximately 10% of all cancer cases, and is the second leading cause of cancer-related deaths worldwide. It is …